Scilight Press

Author Information

Received: 22 Feb 2023 | Accepted: 24 Feb 2023 | Published: 31 Mar 2023

References 

• 1.
  Bailey C.J.; Day C. Metformin: its botanical background. Pract. Diabetes Int. 2004,21:115–117.
• 2.
  Hadden D.R. Goat’s rue—French lilac – Italian fitch –Spanish sainfoin: gallega officinalis and metformin: the
• 3.
  Edinburgh connection. J. R. Coll. Physicians Edinb. 2005,35:258–260.
• 4.
  Watanabe C.K. Studies in the metabolic changes induced by administration of guanidine bases. Influence of injected guanidine hydrochloride upon blood sugar content. J. Biol. Chem. 1918,33:253–265.
• 5.
  Bischoff F., Sahyun M.; Long M.L. Guanidine structure and hypoglycemia. J. Biol. Chem. 1928,81:325–349.
• 6.
  Garcia E.Y. Flumamine, a new synthetic analgesic and antiflu drug. J. Philippine Med. Assoc. 1950,26:287–293.
• 7.
  Pasik C. Jean Sterne: a passion for research. In: Pasik C (ed) Glucophage: serving diabetology for 40 years. Lyon, Groupe Lipha, 1997,pp 29–31.
• 8.
  Luft D.; Schmulling R.M.; Eggstein M. Lactic acidosis in biguanide-treated diabetics. Diabetologia. 1978,14:75–87.
• 9.
  University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Evaluation of phenformin therapy. Diabetes 1975,24(Suppl 1):65–184.
• 10.
  Bailey C.J. Biguanides and NIDDM. Diabetes Care 1992,15:755–772.
• 11.
  DeFronzo R.A. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988,37:667–687.
• 12.
  Reaven G.M. Role of insulin resistance in human disease. Diabetes. 1988,37:1595–1607.
• 13.
  DeFronzo R.A.; Goodman A.M. Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulindependent diabetes mellitus. N. Engl. J. Med .1995,333:541–549.
• 14.
  Nesti L.; and Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr. Metab. Cardiovasc. Dis. 2017,27(8):657-69.
• 15.
  Xu X.; Lu Z.; Fassett J.; Zhang P.; Hu X.; et al. Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase alpha2. Hypertension. 2014,63(4):723-8.
• 16.
  Tzanavari T.; Varela A.; Theocharis S.; Ninou E.; Kapelouzou A.; et al. Metformin protects against infection-induced myocardial dysfunction. Metabolism. 2016,65(10):1447-58.
• 17.
  Soraya H.; Clanachan A.S.; Rameshrad M.; Maleki-Dizaji N.; Ghazi-Khansari M.; et al. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur. J. Pharmacol. 2014,737:77-84.
• 18.
  Loi H.; Boal F.; Tronchere H.; Cinato M.; Kramar S.; et al. Metformin Protects the Heart Against Hypertrophic and Apoptotic Remodeling After Myocardial Infarction. Front. Pharmacol. 2019,10:154.
• 19.
  Driver C.; Bamitale K.D.S.; Kazi A.; Olla M.; Nyane N.A. Cardioprotective Effects of Metformin. J. Cardiovasc. Pharmacol. 2018,72(2):121-7.
• 20.
  Apaijai N.; Pintana H.; Chattipakorn S.C.; and Chattipakorn N. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology. 2012,153(8):3878-85.
• 21.
  Zilinyi R.; Czompa A.; Czegledi A.; Gajtko A.; Pituk D.; et al. The Cardioprotective Effect of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy. Molecules. 2018,23(5).
• 22.
  Ajzashokouhi A.H.; Bostan H.B.; Jomezadeh V.; Hayes A.W.; and Karimi G. A review on the cardioprotective mechanisms of metformin against doxorubicin. Hum. Exp. Tox. 2019,960327119888277.
• 23.
  Jennifer V.; Younghee H.; Brett S. et al. Metformin Inhibits Autophagy/Mitophagy and Antagonizes Doxorubicin-Induced Cardiomyocyte Death. Int. J. Drug Discov. Pharmacol. 2023, 2(1), 5. https://doi.org/10.53941/ijddp.0201005
• 24.
  Swain S.M; Whaley F.S.; and Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003,97(11):2869-79.
• 25.
  Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998,339(13):900-5.
• 26.
  Minotti G.; Menna P.; Salvatorelli E.; Cairo G.; and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004,56(2):185-229.